मूलभूत आँकड़े
| CIK | 1782999 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to PureTech Health plc - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal executi |
|
| August 28, 2025 |
Exhibit 99.2 Interim Management Report and Financial Review Interim Management Report Introduction Refining our model to create more value, more efficiently The first half of 2025 has been a period of meaningful progress and reflection for PureTech. Our work advancing deupirfenidone (LYT-100) to the cusp of Phase 3—supported by compelling open-label extension (OLE) data from the ELEVATE IPF study— |
|
| August 28, 2025 |
For the six months ended June 30, 2025 Exhibit 99.3 Condensed Consolidated Statement of Comprehensive Income/(Loss) (Unaudited) For the six months ended June 30 Note 2025 $000s 2024 $000s Contract revenue 1,851 — Grant revenue — 288 Total revenue 1,851 288 Operating expenses: General and administrative expenses (24,883) (27,758) Research and development expenses (24,900) (38,928) Operating income/(loss) (47,931) (66,398) Other income/( |
|
| August 28, 2025 |
Exhibit 99.1 28 August 2025 PureTech Health plc – Half-Year Report Achieved meaningful progress toward key value inflection points across our diversified portfolio, with multiple programs advancing into or toward late-stage development Launch of Celea Therapeutics continues our proven, capital-efficient model Maintained a strong financial position with $319.6M PureTech level cash, cash equivalents |
|
| July 16, 2025 |
PureTech Health plc PureTech Announces Leadership Transition Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED 16 July 2025 PureTech Health plc PureTech Announces Leadership Transition PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a cl |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal executi |
|
| July 8, 2025 |
PureTech Health plc PureTech Announces Board Change Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED 8 July 2025 PureTech Health plc PureTech Announces Board Change PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-sta |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal executi |
|
| June 16, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2025 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| June 16, 2025 |
PureTech Health plc Results of Annual General Meeting EX-99.1 Exhibit 99.1 16 June 2025 PureTech Health plc Results of Annual General Meeting The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Monday, June 16, 2025. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, inc |
|
| April 30, 2025 |
Exhibit 2.3 Description of Securities The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of PureTech Health plc (“PureTech,” “us,” “our,” “we” or the “Company”) is a summary of the rights of our American Depository Shares and certain provisions of our articles of association in effect as of December 31, 2021 (the “Articles”). This summary |
|
| April 30, 2025 |
SECURED SUBORDINATED CONVERTIBLE PROMISSORY NOTE Exhibit 4.37 THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO T |
|
| April 30, 2025 |
Exhibit 99.1 30 April 2025 PureTech Health plc PureTech Announces Annual Results for Year Ended December 31, 2024 Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy |
|
| April 30, 2025 |
Exhibit 4.36 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version Royalty Purchase Agreement By and Between PureTech Health LLC, as the Seller, and Solely for purposes of Article 4 and Section 10.13 |
|
| April 30, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April, 2025 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal e |
|
| April 30, 2025 |
PURETECH HEALTH PLC PERFORMANCE SHARE PLAN 2023 1. Establishment, Purpose and Types of Awards Puretech Health plc, a public limited company incorporated under English law (the “Company”), hereby establishes the PURETECH HEALTH PLC PERFORMANCE SHARE PLAN (the “Plan”). The purpose of the Plan is to promote the long-term growth and profitability of the Company by (i) providing key individuals with in |
|
| April 30, 2025 |
AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT SONDE HEALTH, INC. Exhibit 4.17 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT SONDE HEALTH, INC. Exhibit 4.17 ACTIVEUS 190549392v.8 TABLE OF CON |
|
| April 30, 2025 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Exhibit 4.25 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 6 2.1 Demand Registration. 6 2.2 Compa |
|
| April 30, 2025 |
PURETECH HEALTH PLC – ANNUAL REPORT AND ACCOUNTS 2024 Exhibit 15.1 BOSTON MA Headquarters PRTC Nasdaq and LSE Relations with Stakeholders 91 Directors’ Report 93 Report of the Nomination Committee 98 Report of the Audit Committee 99 Directors’ Remuneration Report 102 Directors’ Remuneration Policy 106 Annual Report on Remuneration 110 Financial statements Independent Auditor’s Report to the Member |
|
| April 30, 2025 |
Execution Version 10513073.v14 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. ASSET TRANSFER AGREEMENT by and between SEAPORT THERAPEUTICS, INC., on the one hand, and PURETECH HEALTH LLC, and PURETECH LYT, INC. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 30, 2025 |
AMENDED AND RESTATED VOTING AGREEMENT SONDE HEALTH, INC. TABLE OF CONTENTS Exhibit 4.15 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED VOTING AGREEMENT SONDE HEALTH, INC. TABLE OF CONTENTS Page 1. Voting Provisions Regarding the Board 2 1.1 Size |
|
| April 30, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of PureTech Health plc (the “Company”) for the fiscal year ended December 31, 2024 (the “Report”), I, Bharatt Chowrira, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as ado |
|
| April 30, 2025 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT SONDE HEALTH, INC. Exhibit 4.16 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT SONDE HEALTH, INC. ACTIVEUS 190548915v.6 TABLE OF CONTENTS Page 1. Definitions 1 2. |
|
| April 30, 2025 |
PURETECH HEALTH PLC POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 PURETECH HEALTH PLC POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION PureTech Health plc (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of November 8, 2023, (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1.Persons Subject to Policy Th |
|
| April 30, 2025 |
DATED APRIL 24, 2025 PURETECH HEALTH PLC SECURITIES DEALING CODE Exhibit 11.1 CONTENTS INTRODUCTION .................................................................................................................................. 1 EXECUTIVE SUMMARY .................................................................................................................... 1 THE CODE ..................... |
|
| April 30, 2025 |
Financial Statements Seaport Therapeutics, Inc. For the period October 18, 2024 through December 31, 2024 With Report from Independent Auditors Exhibit 99.1 F-1 Seaport Therapeutics, Inc. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Audited Consolidated Financial Statements for the Period of October 18, 2024 through December 31, 2024 Report from Independent Auditors F-2 Consolidated Balance Sheet F- |
|
| April 30, 2025 |
Exhibit 12.1 CERTIFICATION I, Bharatt Chowrira, certify that: 1. I have reviewed this annual report on Form 20-F of PureTech Health plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect |
|
| April 7, 2025 |
PureTech Health plc Statement regarding press speculation Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE “CODE”) AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF TH |
|
| April 7, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April, 2025 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal e |
|
| February 12, 2025 |
AGREEMENT AS TO JOINT FILING OF SCHEDULE 13G EX-1 2 c-ex1.htm EX-1 EXHIBIT INDEX TO SCHEDULE 13G EXHIBIT 1 Agreement among CGML, CGMHBL, CFP, CGM Holdings and Citigroup as to joint filing of Schedule 13G. EXHIBIT 1 AGREEMENT AS TO JOINT FILING OF SCHEDULE 13G Each of the undersigned hereby affirms that it is individually eligible to use Schedule 13G, and agrees that this Schedule 13G is filed on its behalf. Dated: February 12, 2025 Citigroup |
|
| December 16, 2024 |
Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED 16 December 2024 PureTech Health plc PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) a |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| November 12, 2024 |
GB:PRTC / PureTech Health plc / CITIGROUP INC - SC 13G Passive Investment SC 13G 1 sc13gpuretech-ptch.htm SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* Puretech Health Plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) G7297M-10-1 (CUSIP Number) Septe |
|
| November 7, 2024 |
GB:PRTC / PureTech Health plc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* PureTech Health PLC (Name of Issuer) Common Stock (Title of Class of Securities) GB00BY2Z0H74 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| October 21, 2024 |
Exhibit 99.1 21 October 2024 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round Financing led by General Atlantic with participation from other top tier investors Proceeds will support key clinical milestones in Seaport’s pipeline of first and best-in-class neuropsychiatric medicines PureTech Health plc (Nasdaq: PRTC, LSE: P |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exe |
|
| October 11, 2024 |
October 11, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| September 27, 2024 |
Exhibit 99.1 27 September 2024 PureTech Health plc PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults Milestone triggers payments to PureTech totaling $29 million under agreements with Royalty Pharma and PureTech’s Founded Entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb in March 2024, and unlocks potentia |
|
| August 28, 2024 |
Exhibit 99.2 Interim Management Report and Financial Review Interim Management Report Introduction PureTech’s core mission is to give life to new classes of medicine to change the lives of patients with devastating diseases. With this mission in mind, we pioneered the hub-and-spoke business model. Our R&D engine has proven successful in this endeavor, having identified, developed and progressed 29 |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal executi |
|
| August 28, 2024 |
PureTech Health plc Results of Annual General Meeting on 13 June 2024 – Update Statement Exhibit 99.1 28 August 2024 PureTech Health plc Results of Annual General Meeting on 13 June 2024 – Update Statement In accordance with Provision 4 of the UK Corporate Governance Code, PureTech (“PureTech” or the “Company”) today provides an update in respect of the results of its Annual General Meeting (AGM) held on June 13, 2024. While all resolutions were approved by shareholders, more than 20% |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exec |
|
| August 28, 2024 |
Exhibit 99.1 28 August 2024 PureTech Health plc – Half-Year Report Strong progress across PureTech’s portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference cal |
|
| August 28, 2024 |
For the six months ended June 30, 2024 Exhibit 99.3 Condensed Consolidated Statement of Comprehensive Income/(Loss) (Unaudited) For the six months ended June 30 Note 2024 $000s 2023 $000s Contract revenue — 750 Grant revenue 288 2,400 Total revenue 288 3,150 Operating expenses: General and administrative expenses (27,758) (26,166) Research and development expenses (38,928) (53,146) Operating income/(loss) (66,398) (76,163) Other income |
|
| August 22, 2024 |
Exhibit 99.1 22 August 2024 PureTech Health plc PureTech Appoints Michele Holcomb, PhD, to Board of Directors Strategic healthcare leader brings more than 30 years of global experience to PureTech’s Board following notable positions with Cardinal Health, Teva Pharmaceuticals and McKinsey & Company PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biother |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exec |
|
| July 9, 2024 |
AKLI / Akili, Inc. / PureTech Health plc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Akili, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 00974B107 (CUSIP Number) Bharatt Chowrira PureTech Health plc 6 Tide Street, Suite 400 Boston, MA 02210 (617) 482-2333 (Name, Address and Telep |
|
| June 24, 2024 |
PureTech Health plc Completion of Tender Offer & Total Voting Rights Exhibit 99.2 THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. THIS ANNOUNCEMENT CONTAINS INS |
|
| June 24, 2024 |
PureTech Health plc Results of the Tender Offer Exhibit (a)(5)(vi) THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. |
|
| June 24, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 3) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PURETECH HEALTH PLC (Name of Subject Company (Issuer) and Name of Filing Person (Offeror)) Ordinary Shares, par value £0.01 per share American Depositary Shares, each representing 10 ordinary shares, par value £0.01 |
|
| June 24, 2024 |
PureTech Health plc Results of the Tender Offer Exhibit 99.1 THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. THIS ANNOUNCEMENT CONTAINS INS |
|
| June 24, 2024 |
PureTech Health plc Completion of Tender Offer & Total Voting Rights Exhibit (a)(5)(vii) THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execut |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execut |
|
| June 20, 2024 |
Exhibit 99.1 20 June 2024 PureTech Health plc PureTech Announces Change of Board Role Raju Kucherlapati, PhD, distinguished Professor of Medicine at Harvard Medical School, has transitioned to the role of Chair of the Board of Directors on a permanent basis PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing th |
|
| June 13, 2024 |
PureTech Health plc Results of Annual General Meeting Exhibit 99.1 13 June 2024 PureTech Health plc Results of Annual General Meeting The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Thursday, June 13, 2024. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, incorpora |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execut |
|
| June 6, 2024 |
PureTech Health plc Result of General Meeting EX-99.(A)(5)(V) Exhibit (a)(5)(v) 6 June 2024 PureTech Health plc Result of General Meeting PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, is pleased to announce that at the General Meeting of the Company held at 11:00 a.m. New York City time (4:00 p.m. Lond |
|
| June 6, 2024 |
SC TO-I/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PURETECH HEALTH PLC (Name of Subject Company (Issuer) and Name of Filing Person (Offeror)) Ordinary Shares, par value £0.01 per share American Depositary Shares, each representing 10 ordinary shares, par v |
|
| June 6, 2024 |
PureTech Health plc Result of General Meeting EX-99.1 Exhibit 99.1 6 June 2024 PureTech Health plc Result of General Meeting PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, is pleased to announce that at the General Meeting of the Company held at 11:00 a.m. New York City time (4:00 p.m. London time) toda |
|
| June 6, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of princip |
|
| June 4, 2024 |
Exhibit 99.1 4 June 2024 PureTech Health plc Proposed $100 million Tender Offer at 250 pence per Ordinary Share Schedule TO Amendment No. 1 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces further information in connection with its proposed $10 |
|
| June 4, 2024 |
Exhibit (a)(5)(iv) 4 June 2024 PureTech Health plc Proposed $100 million Tender Offer at 250 pence per Ordinary Share Schedule TO Amendment No. |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execut |
|
| June 4, 2024 |
200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco June 4, 2024 Frankfurt Seoul Hamburg Silicon Valley Hong Kong Singapore Houston Tel Aviv London Tokyo Los Angeles Washington, D.C. |
|
| June 4, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PURETECH HEALTH PLC (Name of Subject Company (Issuer) and Name of Filing Person (Offeror)) Ordinary Shares, par value £0.01 per share American Depositary Shares, each representing 10 ordinary shares, par value £0.01 |
|
| May 30, 2024 |
AKLI / Akili, Inc. / PureTech Health plc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akili, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 00974B107 (CUSIP Number) Bharatt Chowrira PureTech Health plc 6 Tide Street, Suite 400 Boston, MA 02210 (617) 482-2333 (Name, Address and Telep |
|
| May 29, 2024 |
Exhibit 99.1 PureTech Health plc PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company Akili to operate as wholly owned subsidiary of Virtual Therapeutics PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that i |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal executi |
|
| May 20, 2024 |
Signature Page to Put and Call Option Agreement EX-99.(d)(1) Exhibit (d)(1) EXECUTION VERSION Put and Call Option Agreement PureTech Health plc the Company Jefferies International Limited Jefferies In relation to Ordinary Shares of PureTech Health plc 20 May 2024 Contents 1. Interpretation 2 2. Tender Offer 6 3. Put and Call Option 6 4. Settlement 7 5. Pricing 11 6. US Broker-Dealer Affiliate 11 7. Tender Offer Materials 11 8. Warranties and Un |
|
| May 20, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exe |
|
| May 20, 2024 |
EX-99.(a)(1)(i) Table of Contents Exhibit (a)(1)(i) THIS CIRCULAR AND ANY ACCOMPANYING TENDER FORM AND FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or about what action to take, you should immediately seek your own professional advice from your stockbroker, bank, fund manager, solicitor, accountant or other appropriat |
|
| May 20, 2024 |
EX-99.(a)(1)(iii) Exhibit (a)(1)(iii) PURETECH ADS LETTER OF TRANSMITTAL to accompany American Depositary Receipts (“ADRs”) evidencing American Depositary Shares (“PureTech ADSs”) representing ordinary shares of of PureTech Health plc Pursuant to a Capital Return by way of Jefferies International Limited’s Offer (the “Offer”) to Purchase Ordinary Shares of PureTech Health plc (“PureTech”) Dated Ma |
|
| May 20, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PURETECH HEALTH PLC (Name of Subject Company (Issuer) and Name of Filing Person (Offeror)) Ordinary Shares, par value £0.01 per share American Depositary Shares, each representing 10 ordinary shares, par value £0.01 per share (Title |
|
| May 20, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FILING FEE Schedule TO-I (Form Type) PureTech Health plc (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation(1) Fee Rate (per million) Amount of Filing Fee(2) Fees to Be Paid $100,000,000 $147. |
|
| May 20, 2024 |
EX-99.(a)(1)(ii) Exhibit (a)(1)(ii) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the Tender Offer or about what action to take, you should immediately seek your own professional advice from your stockbroker, bank, fund manager, solicitor, accountant or other appropriately qualified independent financial adviser authorised under the Financial Servi |
|
| May 20, 2024 |
EX-99.(a)(1)(iv) Exhibit (a)(1)(iv) LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES PureTech Health plc Proposed Capital Return of U.S. $100 million to Shareholders by Way of a Tender Offer for Ordinary Shares (including Ordinary Shares represented by American Depositary Shares) at 250 Pence per Ordinary Share THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE WITH RESPEC |
|
| May 20, 2024 |
PureTech Health Plc 2024 Tender Offer Frequently Asked Questions EX-99.(a)(5)(iii) Exhibit (a)(5)(iii) PureTech Health Plc 2024 Tender Offer Frequently Asked Questions General Q1. What is a Tender Offer? A1. A tender offer is an open bid for all shareholders to sell shares back to PureTech. Q2. What is the General Meeting? A2. Certain resolutions, necessary for PureTech to approve the repurchase of Ordinary Shares (including Ordinary Shares represented by the P |
|
| May 20, 2024 |
EX-99.(a)(1)(v) Exhibit (a)(1)(v) LETTER TO CLIENTS FOR TENDER OF PURETECH HEALTH PLC ADSs PureTech Health plc Proposed Capital Return of U.S. $100 million to Shareholders by Way of a Tender Offer for Ordinary Shares (including Ordinary Shares represented by American Depositary Shares) at 250 Pence per Ordinary Share THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE WITH RESPECT TO THE PURETECH ADSs AT |
|
| May 20, 2024 |
EX-99.(a)(5)(ii) Exhibit (a)(5)(ii) THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. 20 May 2024 PureTech Health plc Launch of Proposed $100 million Tender Offer at 250 pence per Ordinary Share Notice of General Mee |
|
| May 20, 2024 |
EX-99.1 Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. 20 May 2024 PureTech Health plc Launch of Proposed $100 million Tender Offer at 250 pence per Ordinary Share Notice of General Meeting PureTech H |
|
| April 25, 2024 |
PURETECH HEALTH PLC POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 PURETECH HEALTH PLC POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION PureTech Health plc (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of November 8, 2023, (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1.Persons Subject to Policy Th |
|
| April 25, 2024 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT SONDE HEALTH, INC. Exhibit 4.16 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT SONDE HEALTH, INC. ACTIVEUS 190548915v.6 TABLE OF CONTENTS Page 1. Definitions 1 2. |
|
| April 25, 2024 |
Exhibit 12.2 Certification I, Bharatt Chowrira, certify that: 1. I have reviewed this annual report on Form 20-F of PureTech Health plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execu |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 25, 2024 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Exhibit 4.25 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 6 2.1 Demand Registration. 6 2.2 Compa |
|
| April 25, 2024 |
Exhibit 4.36 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version Royalty Purchase Agreement By and Between PureTech Health LLC, as the Seller, and Solely for purposes of Article 4 and Section 10.13 |
|
| April 25, 2024 |
Exhibit 12.1 Certification I, Bharatt Chowrira, certify that: 1. I have reviewed this annual report on Form 20-F of PureTech Health plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect |
|
| April 25, 2024 |
PURETECH HEALTH PLC – ANNUAL REPORT AND ACCOUNTS 2023 Exhibit 15.1 BOSTON MA Headquarters PRTC Nasdaq and LSE Directors’ Report 93 Report of the Nomination Committee 98 Report of the Audit Committee 99 Directors’ Remuneration Report 102 Directors’ Remuneration Policy 106 Annual Report on Remuneration 113 Financial statements Independent Auditor’s Report to the Members of PureTech Health plc 123 Co |
|
| April 25, 2024 |
PURETECH HEALTH PLC PERFORMANCE SHARE PLAN 2023 1. Establishment, Purpose and Types of Awards Puretech Health plc, a public limited company incorporated under English law (the “Company”), hereby establishes the PURETECH HEALTH PLC PERFORMANCE SHARE PLAN (the “Plan”). The purpose of the Plan is to promote the long-term growth and profitability of the Company by (i) providing key individuals with in |
|
| April 25, 2024 |
Exhibit 4.23 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION AKILI INTERACTIVE LABS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHT |
|
| April 25, 2024 |
Exhibit 99.1 25 April 2024 PureTech Health plc PureTech Announces Annual Results for Year Ended December 31, 2023 Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for Seaport, and the $14 billion acquisition of Karuna by Bristol Myers Squibb Robust balance she |
|
| April 25, 2024 |
Execution Version 10513073.v14 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. ASSET TRANSFER AGREEMENT by and between SEAPORT THERAPEUTICS, INC., on the one hand, and PURETECH HEALTH LLC, and PURETECH LYT, INC. |
|
| April 25, 2024 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of PureTech Health plc (the “Company”) for the fiscal year ended December 31, 2023 (the “Report”), I, Bharatt Chowrira, Chief Executive Officer of the Company, hereby certify, pursuant to 18 |
|
| April 25, 2024 |
Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of PureTech Health plc (the “Company”) for the fiscal year ended December 31, 2023 (the “Report”), I, Bharatt Chowrira, Chief Executive Officer of the Company, hereby certify, pursuant to 18 |
|
| April 25, 2024 |
AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT SONDE HEALTH, INC. Exhibit 4.17 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT SONDE HEALTH, INC. Exhibit 4.17 ACTIVEUS 190549392v.8 TABLE OF CON |
|
| April 25, 2024 |
AMENDED AND RESTATED VOTING AGREEMENT SONDE HEALTH, INC. TABLE OF CONTENTS Exhibit 4.15 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED VOTING AGREEMENT SONDE HEALTH, INC. TABLE OF CONTENTS Page 1. Voting Provisions Regarding the Board 2 1.1 Size |
|
| April 25, 2024 |
Exhibit 2.3 Description of Securities The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of PureTech Health plc (“PureTech,” “us,” “our,” “we” or the “Company”) is a summary of the rights of our American Depository Shares and certain provisions of our articles of association in effect as of December 31, 2021 (the “Articles”). This summary |
|
| April 25, 2024 |
SECURED SUBORDINATED CONVERTIBLE PROMISSORY NOTE Exhibit 4.37 THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO T |
|
| April 25, 2024 |
Exhibit 4.24 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***] FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version AKILI INTERACTIVE LABS, INC. AMENDED AND RESTATED FIRST REFUSAL AND CO-SALE AGREEMENT This AMENDED AND RESTATED FIRST REFUSAL AND CO- |
|
| April 9, 2024 |
Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. 9 April 2024 PureTech Health plc PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions Bh |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execu |
|
| March 19, 2024 |
Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED PureTech Proposes $100 Million Capital Return Proposed capital return of $100 million by way of a Tender Offer at 250 pence per Ordinary Share Premium of |
|
| March 19, 2024 |
Exhibit 99.1 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED PureTech Proposes $100 Million Capital Return Proposed capital return of $100 million by way of a Tender Offer at 250 pence per Ordinary Share Premium of |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execu |
|
| March 19, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PURETECH HEALTH PLC (Name of Subject Company (Issuer) and Name of Filing Person (Offeror)) Ordinary Shares, par value £0.01 per share (Title of Class of Securities) G7297M101 (CUSIP Number of Class of Securities) Daphne Zohar Chief E |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execu |
|
| March 18, 2024 |
Exhibit 99.1 18 March 2024 PureTech Health plc Bristol Myers Squibb Completes Acquisition of PureTech’s Founded Entity Karuna Therapeutics for $14 Billion Acquisition centered on KarXT, which was invented at PureTech, as a potential first-in-class treatment for schizophrenia in adults PureTech to receive approximately $293 million gross proceeds from Karuna equity position in addition to being eli |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| February 12, 2024 |
PTCHF / PureTech Health plc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* PureTech Health PLC (Name of Issuer) Common Stock (Title of Class of Securities) G7297M101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January, 2024 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exe |
|
| January 4, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principa |
|
| December 20, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principa |
|
| December 20, 2023 |
Exhibit 99.1 20 December 2023 PureTech Health plc PureTech Year End Update and Outlook for 2024 Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024 Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline Robust balance sheet position with estimated Consolidated Cash, Cash Equivalents and Short-Term Investments at year en |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exe |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal e |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exec |
|
| August 29, 2023 |
prtc2023halfyearresults PureTech Health plc – Half-Year Report Strong progression of PureTech’s Wholly Owned Pipeline, with three clinical-stage therapeutic candidates being evaluated across four clinical trials to address large patient needs in pulmonary, oncology and CNS indications, and a growing pipeline of four additional preclinical CNS programs Advancements across Founded Entities, including Karuna’s third positive registrational trial for KarXT and planned filing for FDA approval, Akili’s commercial release of EndeavorOTCTM for adults with ADHD, Gelesis’ application to make Plenity® available without a prescription, additional positive results from Vor’s Phase 1/2a leukemia trial and Vedanta’s $106. |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal executi |
|
| August 2, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execut |
|
| June 14, 2023 |
PureTech Health plc Results of Annual General Meeting Exhibit 99.1 13 June 2023 PureTech Health plc Results of Annual General Meeting The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Tuesday, June 13, 2023. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, incorporat |
|
| June 14, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| June 12, 2023 |
EX-99.1 Exhibit 99.1 PureTech Health plc 6 Tide Street, Suite 400, Boston, MA 02210 Tel 617.482.2333 Fax 617.482.3337 puretechhealth.com This letter is being sent to the shareholders of PureTech Health plc (the ‘Company’) for information only and no action is required to be taken. If you have sold or transferred all of your ordinary shares in the Company you should pass this document to the purcha |
|
| June 12, 2023 |
Reference - AR-1762 Document Classification – KPMG Highly Confidential EX-99.2 Exhibit 99.2 KPMG LLP Audit 15 Canada Square London E14 SGL United Kingdom Tel +44 (0) 20 7311 1000 Fax +44 (0) 20 7311 3311 Private & confidential PureTech Health plc 8th Floor 20 Farringdon Street London EC4A 4AB Our ref AR-1762 Contact Bob Seale [email protected] 31 May 2023 Dear Sir/Madam, Statement to PureTech Health plc (no. 09582467) on ceasing to hold office as auditors pursuant |
|
| June 12, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| June 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of |
|
| May 3, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal e |
|
| April 28, 2023 |
Exhibit 4.18 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT SONDE HEALTH, INC. Exhibit 4.18 ACTIVEUS 190549392v.8 TABLE OF CON |
|
| April 28, 2023 |
Form of Secured Subordinated Convertible Promissory Note of Vedanta Biosciences, Inc. Exhibit 4.38 THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO T |
|
| April 28, 2023 |
Annual Report and Accounts 2022 ex151puretecharadecember P U R E T E C H H E A L T H P L C – A N N U A L R E P O R T A N D A C C O U N T S 2 0 2 2 ptarcoverart2023final. |
|
| April 28, 2023 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of PureTech Health plc (the “Company”) for the fiscal year ended December 31, 2022 (the “Report”), I, Daphne Zohar, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 28, 2023 |
PureTech Health plc PureTech Announces Annual Results for Year Ended December 31, 2022 Exhibit 99.1 28 April 2023 PureTech Health plc PureTech Announces Annual Results for Year Ended December 31, 2022 Strong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million1 and consolidated cash, cash equivalents and short-term investments of $350.1 million,2 as of December 31, 2022. Rapid advancement of PureTech’s Wholly Owned Pipeline, with four |
|
| April 28, 2023 |
2023 by and among Vedanta Biosciences, Inc. and the investors and noteholders party thereto Exhibit 4.26 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 6 2.1 Demand Registration. 6 2.2 Compa |
|
| April 28, 2023 |
Exhibit 4.16 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED VOTING AGREEMENT SONDE HEALTH, INC. TABLE OF CONTENTS Page 1. Voting Provisions Regarding the Board 2 1.1 Size |
|
| April 28, 2023 |
Description of Registrant’s Securities Exhibit 2.3 Description of Securities The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of PureTech Health plc (“PureTech,” “us,” “our,” “we” or the “Company”) is a summary of the rights of our American Depository Shares and certain provisions of our articles of association in effect as of December 31, 2021 (the “Articles”). This summary |
|
| April 28, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal e |
|
| April 28, 2023 |
Exhibit 4.25 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***] FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version AKILI INTERACTIVE LABS, INC. AMENDED AND RESTATED FIRST REFUSAL AND CO-SALE AGREEMENT This AMENDED AND RESTATED FIRST REFUSAL AND CO- |
|
| April 28, 2023 |
Exhibit 4.17 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT SONDE HEALTH, INC. ACTIVEUS 190548915v.6 TABLE OF CONTENTS Page 1. Definitions 1 2. |
|
| April 28, 2023 |
Exhibit 4.24 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION AKILI INTERACTIVE LABS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHT |
|
| April 28, 2023 |
Letter from KPMG LLP to the Securities and Exchange Commission Exhibit 15.2 April 28, 2023 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We are currently principal accountants for PureTech Health PLC and, under the date of April 27. 2023, we reported on the consolidated financial statements of PureTech Health PLC as of and for each of the years in the three-year period ended December 31, 2022, and the effectiveness of interna |
|
| April 28, 2023 |
Exhibit 4.37 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version Royalty Purchase Agreement By and Between PureTech Health LLC, as the Seller, and Solely for purposes of Article 4 and Section 10.13 |
|
| April 28, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Daphne Zohar, certify that: 1. I have reviewed this annual report on Form 20-F of PureTech Health plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or |
|
| April 28, 2023 |
F-1 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm F- 2 Consolidated Balance Sheets as of December 31, 2022 and 2021 F- 3 Consolidated Statements of Operations for the years ended December 31, 2022 and 2021 F- 4 Consolidated Statements of Comprehensive Loss for the years ended December 31, 2022 and 2021 F- 5 Consolidated Statements of Noncontrolling Interest, Redeemable Convertible Preferred Stock and Stockholders’ Deficit for the years ended December 31, 2022 and 2021 F- 6 Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021 F- 7 Notes to Consolidated Financial Statements F- 8 Exhibit 99. |
|
| April 28, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bharatt Chowrira, certify that: 1. I have reviewed this annual report on Form 20-F of PureTech Health plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fac |
|
| April 28, 2023 |
Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of PureTech Health plc (the “Company”) for the fiscal year ended December 31, 2022 (the “Report”), I, Bharatt Chowrira, President and Chief Business, Finance and Operating Officer of the Comp |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execu |
|
| March 23, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal e |
|
| March 23, 2023 |
EX-99.1 Exhibit 99.1 23 March 2023 PureTech Health plc PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds. PureTech retains its current equity stake in Karuna in addition to m |
|
| March 20, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal e |
|
| March 20, 2023 |
EX-99.1 Exhibit 99.1 20 March 2023 PureTech Health plc PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a sid |
|
| March 2, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principa |
|
| February 10, 2023 |
PTCHF / PureTech Health PLC / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* PureTech Health PLC (Name of Issuer) Common Stock (Title of Class of Securities) G7297M101 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 3, 2023 |
6-K 1 d443731d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January, 2023 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| December 22, 2022 |
EX-99.1 2 d398660dex991.htm EX-99.1 Exhibit 99.1 22 December 2022 PureTech Health plc PureTech Provides End of Year Report on Key Progress Rapid advancement of PureTech’s Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and t |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| November 10, 2022 |
PureTech Health plc Director Declaration EX-99.1 2 d394893dex991.htm EX-99.1 Exhibit 99.1 10 November 2022 PureTech Health plc Director Declaration Pursuant to Listing Rule 9.6.14(2), PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) notes that Christopher Viehbacher, a Non-Executive Director and Chair of the Company’s Board, has been appointed as President and Chief Executive Officer and a member of the Board o |
|
| November 10, 2022 |
6-K 1 d394893d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 |
|
| November 3, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal |
|
| October 11, 2022 |
EX-99.1 2 d288770dex991.htm EX-99.1 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 (“MAR”). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THE I |
|
| October 11, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal |
|
| October 11, 2022 |
Nektar Therapeutics (“Nektar”) Rule 2.8 Announcement EX-99.2 3 d288770dex992.htm EX-99.2 Exhibit 99.2 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE “CODE”) THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE R |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exe |
|
| October 7, 2022 |
PureTech Health plc Statement regarding recent press speculation EX-99.1 2 d367316dex991.htm EX-99.1 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE “CODE”) AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION T |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal e |
|
| September 2, 2022 |
6-K 1 d325321d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 ( |
|
| August 30, 2022 |
AKLI / Akili Inc / PureTech Health plc - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Akili, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 00974B107 (CUSIP Number) Daphne Zohar PureTech Health plc 6 Tide Street, Suite 400 Boston, MA 02210 (617) 482-2333 (Name, Address and Telephone Number of |
|
| August 30, 2022 |
EX-99.1 2 d288752dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of t |
|
| August 25, 2022 |
6-K 1 a062022jun20226kprtcsemian.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachu |
|
| August 25, 2022 |
25 August 2022 PureTech Health plc ? Half-Year Report Strong capital base with PureTech Level Cash and Cash Equivalents of $341. |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exec |
|
| August 22, 2022 |
EX-99.1 Exhibit 99.1 22 August 2022 PureTech Health plc PureTech Founded Entity Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I Akili, Inc. common stock to begin trading on Nasdaq under the ticker symbol “AKLI” on August 22, 2022 Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatme |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exec |
|
| August 9, 2022 |
Exhibit 99.1 9 August 2022 PureTech Health plc PureTech To Receive up to Approximately $115.4 Million from Sale of a Portion of Founded Entity Shares PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (?PureTech? or the ?Company?), a biotherapeutics company dedicated to changing the treatment paradigm for patients with devastating diseases, today announces that it has raised aggregate proceeds of up to |
|
| August 4, 2022 |
6-K 1 d384115d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Ad |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execut |
|
| June 15, 2022 |
PureTech Health plc Results of Annual General Meeting EX-99.1 2 d314669dex991.htm EX-99.1 Exhibit 99.1 15 June 2022 PureTech Health plc Results of Annual General Meeting The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 15, 2022. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a pol |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execut |
|
| June 3, 2022 |
6-K 1 d322260d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Add |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal executi |
|
| May 9, 2022 |
PureTech Health plc PureTech Announces Share Buyback Programme Update EX-99.1 2 d355904dex991.htm EX-99.1 Exhibit 99.1 9 May 2022 PureTech Health plc PureTech Announces Share Buyback Programme Update PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, announces that, in connection with th |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal executi |
|
| May 5, 2022 |
EX-99.1 2 d338456dex991.htm EX-99.1 Exhibit 99.1 5 May 2022 PureTech Health plc PureTech Announces Share Buyback Programme of up to $50 million Previous cash runway guidance into the first quarter of 2025 remains in place PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising hig |
|
| April 26, 2022 |
EX-99.1 11 ex991gelesisfinancials1.htm EX-99.1 F-1 Confidential Xcc Gelesis, Inc. and subsidiaries Consolidated financial statements as of and for the years ended December 31, 2021 and 2020 Exhibit 99.1 F-2 Confidential GELESIS, INC. INDEX TO FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm ................................................................................ |
|
| April 26, 2022 |
EX-99.1 2 d142407dex991.htm EX-99.1 Exhibit 99.1 PureTech Announces Annual Results for Year Ended December 31, 2021 Strong capital base with PureTech level cash and cash equivalents of $418.9 million1 and consolidated cash and cash equivalents of $465.7 million2 as of December 31, 2021 Rapidly progressing pipeline of 27 therapeutics and therapeutic candidates, across Wholly Owned and Founded Entit |
|
| April 26, 2022 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Daphne Zohar, certify that: 1. I have reviewed this annual report on Form 20-F of PureTech Health plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 26, 2022 |
Exhibit 4.24 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION AKILI INTERACTIVE LABS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHT |
|
| April 26, 2022 |
Exhibit 4.25 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***] FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version AKILI INTERACTIVE LABS, INC. AMENDED AND RESTATED FIRST REFUSAL AND CO-SALE AGREEMENT This AMENDED AND RESTATED FIRST REFUSAL AND CO- |
|
| April 26, 2022 |
Description of Registrant’s Securities Exhibit 2.3 Description of Securities The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of PureTech Health plc (“PureTech,” “us,” “our,” “we” or the “Company”) is a summary of the rights of our American Depository Shares and certain provisions of our articles of association in effect as of December 31, 2021 (the “Articles”). This summary |
|
| April 26, 2022 |
Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of PureTech Health plc (the “Company”) for the fiscal year ended December 31, 2021 (the “Report”), I, George Farmer, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S |
|
| April 26, 2022 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of PureTech Health plc (the “Company”) for the fiscal year ended December 31, 2021 (the “Report”), I, Daphne Zohar, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S. |
|
| April 26, 2022 |
Exhibit 12.2 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, George Farmer, certify that: 1. I have reviewed this annual report on Form 20-F of PureTech Health plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact o |
|
| April 26, 2022 |
Annual Report and Accounts 202 P ureTech H ealth p lc A nnual rep ort and acco unts 2021 PURETECH HEALTH PLC – ANNUAL REPORT AND ACCOUNTS 2021 ptcover2230. |
|
| April 26, 2022 |
Exhibit 4.26 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 6 2.1 Demand Registration. 6 2.2 Compa |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal execu |
|
| March 24, 2022 |
Exhibit 99.1 24 March 2022 PureTech Health plc PureTech Appoints Sharon Barber-Lui to Board of Directors & Audit Committee Seasoned life sciences expert brings further global portfolio management and financial expertise from 20 years at Merck & Co. Inc. to the PureTech board Ms. Barber-Lui will also become chair of the Audit Committee of the board BOSTON, March 24, 2022 ? PureTech Health plc (Nasd |
|
| March 24, 2022 |
6-K 1 d283748d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (A |
|
| February 11, 2022 |
PTCHF / PureTech Health PLC / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* PureTech Health PLC (Name of Issuer) Common Stock (Title of Class of Securities) G7297M101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 26, 2022 |
EX-99.1 2 d291776dex991.htm EX-99.1 Exhibit 99.1 26 January 2022 PureTech Health plc PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I In addition to PureTech’s advanced Wholly Owned Pipeline, Founded Entities are an additional source of value and Akili is now set to join the growing |
|
| January 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exe |
|
| January 14, 2022 |
6-K 1 d225466d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January, 2022 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 |
|
| January 14, 2022 |
EX-99.1 2 d225466dex991.htm EX-99.1 Exhibit 99.1 14 January 2022 PureTech Health plc PureTech Founded Entity Gelesis, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with Capstar Proceeds from this transaction will be used to further support the national launch of Plenity® Gelesis will begin trading on the New Y |
|
| November 10, 2021 |
EX-99.1 2 d258435dex991.htm EX-99.1 Exhibit 99.1 10 November 2021 PureTech Health plc PureTech Receives Approximately $100 Million from Sale of a Portion of Founded Entity Shares PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announces that it has sold 750,000 shares of its Founded Entity, Karuna Therapeutics (“Karuna,” |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November, 2021 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal ex |
|
| November 9, 2021 |
6-K 1 d256710d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November, 2021 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 |
|
| November 9, 2021 |
Exhibit 99.1 9 November 2021 PureTech Health plc PureTech Announces Participation at the Jefferies London Healthcare Conference Company reports PureTech Level Cash and Cash Equivalents of $387.3 million1 and Consolidated Cash and Cash Equivalents of $441.0 million2 as of September 30, 2021 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (?PureTech? or the ?Company?), a clinical-stage biotherapeutics |
|
| October 12, 2021 |
PureTech Health plc Block Listing Application EX-99.1 2 d201217dex991.htm EX-99.1 Exhibit 99.1 12 October 2021 PureTech Health plc Block Listing Application PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech ” or “the Company”) announces that an application has been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock E |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October, 2021 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant?s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal exe |
|
| August 24, 2021 |
EX-99.1 2 ex991.htm EX-99.1 24 August 2021 PureTech Health plc – Half-Year Report Strong capital base and cash runway expected into the first quarter of 2025, with PureTech level cash and cash equivalents of $409.7 million1 and consolidated cash and cash equivalents of $439.8 million2 as of June 30, 2021 Continued advancement of PureTech’s Wholly Owned Programs, with two Phase 2 and four Phase 1 c |
|
| August 24, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2021 Commission File Number 001-39670 PURETECH HEALTH PLC 6 Tide Street, Suite 400 Boston, Massachusetts 02210 Attention: Chief Executive Officer (617) 482-2333 (Address of principal executive offices) |
|
| July 19, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2021 Commission File Number 001-39670 PURETECH HEALTH PLC 6 Tide Street, Suite 400 Boston, Massachusetts 02210 Attention: Chief Executive Officer (617) 482-2333 (Address of principal executive offices) |
|
| July 19, 2021 |
EX-99.1 2 d195649dex991.htm EX-99.1 Exhibit 99.1 19 July 2021 PureTech Health plc PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp. Public listing of Gelesis, along with Karuna Therapeutics (Nasdaq: KRTX) and Vor Biopharma (Nasdaq: VOR), five other private Founded Entities and advanced Wholly Owned |
|
| May 27, 2021 |
PureTech Health plc Results of Annual General Meeting EX-99.1 2 d152382dex991.htm EX-99.1 Exhibit 99.1 27 May 2021 PureTech Health plc Results of Annual General Meeting The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Thursday, May 27, 2021. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. |
|
| May 27, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number 001-39670 PURETECH HEALTH PLC 6 Tide Street, Suite 400 Boston, Massachusetts 02210 Attention: Chief Executive Officer (617) 482-2333 (Address of principal executive offices) I |
|
| April 15, 2021 |
As filed with the Securities and Exchange Commission on April 15, 2021. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? |
|
| April 15, 2021 |
Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of PureTech Health plc (the ?Company?) on Form 20-F for the period ended December 31, 2020 (the ?Report?), I, George Farmer, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. S |
|
| April 15, 2021 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Daphne Zohar, certify that: 1. I have reviewed this annual report on Form 20-F of PureTech Health plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or |
|
| April 15, 2021 |
Code of Business Conduct and Ethics Exhibit 11.1 PURETECH HEALTH PLC Code of Business Conduct and Ethics – Chief Executive Officer’s Message November 9, 2020 Dear Colleague: Our company’s reputation and continued success is dependent upon the conduct of its employees, directors and certain designated agents. When acting on behalf of PureTech Health plc, each employee, director and designated agent, as a custodian of the Company’s go |
|
| April 15, 2021 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of PureTech Health plc (the ?Company?) on Form 20-F for the period ended December 31, 2020 (the ?Report?), I, Daphne Zohar, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Se |
|
| April 15, 2021 |
EX-2.1 2 ex21puretechhealthplc-de.htm EX-2.1 11197385v.7 DEPOSIT AGREEMENT by and among PURETECH HEALTH PLC and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of November 11, 2020 Exhibit 2.1 i 11197385v.7 TABLE OF CONTENTS ARTICLE I DEFINITIONS ............................................................................ |
|
| April 15, 2021 |
Annual Report and Accounts 2020 EX-15.1 9 ex151puretechhealthannua.htm EX-15.1 PureTech Health 6 Tide Street Suite 400 Boston MA 02210 Tel: +1 617 482 2333 Email: [email protected] P u reTe ch H e a lth p lc A n n u al re p o rt an d acco u n ts 2 0 2 0 P U R E T E C H H E A L T H P L C - A N N U A L R E P O R T A N D A C C O U N T S 2 0 2 0 coverpuretech210315.indd 1 18/03/2021 14:46 Exhibit 15.1 1 Our Founded Entities ar |
|
| April 15, 2021 |
Description of Registrant’s Securities EX-2.3 3 ex23descriptionofsecurities.htm EX-2.3 Exhibit 2.3 Description of Securities The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of PureTech Health plc (“PureTech,” “us,” “our,” “we” or the “Company”) is a summary of the rights of our American Depository Shares and certain provisions of our articles of association in effect as of |
|
| April 15, 2021 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, George Farmer, certify that: 1. I have reviewed this annual report on Form 20-F of PureTech Health plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact o |
|
| March 18, 2021 |
PureTech Health plc PureTech Announces Board Member Retirement EX-99.1 2 d114393dex991.htm EX-99.1 Exhibit 99.1 18 March 2021 PureTech Health plc PureTech Announces Board Member Retirement PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announces that Stephen Muniz, Esq., |
|
| March 18, 2021 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2021 Commission File Number 001-39670 PURETECH HEALTH PLC 6 Tide Street, Suite 400 Boston, Massachusetts 02210 Attention: Chief Executive Officer (617) 482-2333 (Address of principal executive offices) |
|
| March 15, 2021 |
PureTech Health plc Notice of Results EX-99.1 2 d128498dex991.htm EX-99.1 Exhibit 99.1 15 March 2021 PureTech Health plc Notice of Results PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to publish its annual report and financial results on Thursday, April 15, 2021 at 2:00 AM EDT / 7:00 AM BST. The report will include the Company’s financial results for the year ended December 31, 2020 as well as its |
|
| March 15, 2021 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March, 2021 Commission File Number 001-39670 PURETECH HEALTH PLC 6 Tide Street, Suite 400 Boston, Massachusetts 02210 Attention: Chief Executive Officer (617) 482-2333 (Address of principal executive offices |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(b) AND AMENDMENTS FILED THERETO FILED PURSUANT TO RULE 13D-2(b) Under the Securities Exchange Act of 1934 (Amendment No. )* PureTech Health PLC (Name of Issuer) Common Stock (Title of Classes of Securities) G7297M101 (CUSIP Number) December 31 |
|
| February 16, 2021 |
JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd. |
|
| February 10, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Karuna Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 48576A100 (CUSIP Number) PureTech Health LLC 6 Tide Street, Suite 400 Boston, MA 02210 (617) 482-2333 (Name, Address and Telephon |
|
| February 10, 2021 |
EX-99.1 2 d129486dex991.htm EX-99.1 Exhibit 99.1 10 February 2021 PureTech Health plc PureTech Receives Approximately $118 Million from Sale of Portion of Founded Entity Shares PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating |
|
| February 10, 2021 |
Current Report of Foreign Issuer - 6-K 6-K 1 d129486d6k.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For February 10, 2021 Commission File Number 001-39670 PURETECH HEALTH PLC 6 Tide Street, Suite 400 Boston, Massachusetts 02210 Attention: Chief Executive Officer (617) 482-2333 (Address of principal |
|
| February 5, 2021 |
EX-99.1 2 d108074dex991.htm EX-99.1 Exhibit 99.1 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 5 February 2021 PureTech Health plc PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering PureTech He |
|
| February 5, 2021 |
Current Report of Foreign Issuer - 6-K 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For February 5, 2021 Commission File Number 001-39670 PURETECH HEALTH PLC 6 Tide Street, Suite 400 Boston, Massachusetts 02210 Attention: Chief Executive Officer (617) 482-2333 (Address of principal executive offices) In |
|
| January 29, 2021 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For January 29, 2021 Commission File Number 001-39670 PURETECH HEALTH PLC 6 Tide Street, Suite 400 Boston, Massachusetts 02210 Attention: Chief Executive Officer (617) 482-2333 (Address of principal executive offices) Indica |
|
| January 29, 2021 |
EX-99.1 2 d16196dex991.htm EX-99.1 Exhibit 99.1 29 January 2021 PureTech Health plc PureTech Adds Bharatt Chowrira, PureTech’s President and Chief of Business and Strategy, to Board of Directors PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicine |
|
| November 9, 2020 |
20FR12B/A Table of Contents As filed with the Securities and Exchange Commission on November 9, 2020. |
|
| November 9, 2020 |
Form of American Depositary Receipt (included in Exhibit 4.1) EX-4.1 Exhibit 4.1 DEPOSIT AGREEMENT by and among PURETECH HEALTH PLC and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [•], 2020 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 2 Section 1.2 “Affiliate” 2 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 2 Section 1.4 “A |
|
| November 2, 2020 |
As filed with the Securities and Exchange Commission on November 2, 2020 Registration No. |
|
| November 2, 2020 |
EX-99.(A) 2 e620041ex99-a.htm Exhibit (a) DEPOSIT AGREEMENT by and among PURETECH HEALTH PLC and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [●], 2020 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 2 Section 1.2 “Affiliate” 2 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Recei |
|
| November 2, 2020 |
Exhibit (d) November 2, 2020 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) by the legal entity created by the Deposit Agreement (as hereinafter defined) for the purpose of registering under the Un |
|
| October 27, 2020 |
EX-10.17 Exhibit 10.17 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. FOLLICA, INCORPORATED FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Dated as of July 19, 2019 FIFTH AMENDED AND RESTARTED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. |
|
| October 27, 2020 |
EX-10.25 Exhibit 10.25 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT SONDE HEALTH, INC. TABLE OF CONTENTS Page 1. Definitions 1 2. Agreement Among the Company, the Investors and the Key Holders 3 2.1 Right of |
